Oral cancer patients with fewer circulating tumor cells live longer than those with more: The Tribune India
Pune, March 27
A study by a team of Indian researchers found that oral cancer patients with lower numbers of circulating tumor cells (CTCs) in the blood live longer than patients with higher numbers of these cells .
The four-year study, among the largest head and neck cancer clinical trials in which 500 patients were analyzed, was led by Dr Pankaj Chaturvedi of Tata Memorial Hospital in Mumbai, Dr Jayant Khandare and a team from Actorius OncoDiscover Technology based in Pune. .
“A total of 152 patients with oral cancer were analyzed and 1.5ml of blood per patient was monitored for the presence of CTCs,” Khandare told PTI.
“The study showed that patients with more than 20 CTCs per 1.5ml of blood are more likely to have advanced disease and lymph node metastases (cancer cells breaking away from where they originated). formed for the first time), while patients with less than 12 CTCs per 1.5 ml of blood survive longer,” he said.
The study was published recently in the international peer-reviewed journal Triple OOO, he added.
According to the national cancer registry, there are about 14 lakh cancer patients in India and about nine percent of them (1.2 lakh) are in Maharashtra, Khandare said.
Cancer cases and deaths in Maharashtra have increased by 11,306 and 5,727 respectively over the past three years, a collective increase of around 8%, he added.
The OncoDiscover test, funded by the government through the Biotech Ignition Grant and the Department of Biotechnology’s Small Business Industry Research Initiative, is the only CTC test approved by the Comptroller General of Medicines of India under the Medical Devices Rules of 2017, he said.
The test is used to detect CTCs for the diagnosis of cancers like head and neck, breast, lung, colon and rectum, Khandare said. “Maharashtra Health Minister, Rajesh Tope has shown interest in our work and will visit our facility in Pune soon,” he added.